Rare Disease Trial, Recruiting NCT06360913 Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT06360913
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People of any age (from newborns to the elderly) who are not thought to have a rare disease and can provide a blood spot sample from routine newborn screening (note: for newborns, only leftover blood spot samples are used — no urine sample is needed, and no consent form is required for this group)
  • People of any age (from newborns to the elderly) who have been confirmed to have a genetic metabolic disease or another rare disease where a metabolic (body chemistry) problem is suspected, with genetic test results to confirm the diagnosis
  • People of any age (from newborns to the elderly) who have been diagnosed with autism spectrum disorder, assessed using standard diagnostic guidelines
  • People of any age (from newborns to the elderly) who are suspected of having a genetic metabolic disease or rare disease with a possible body chemistry problem, but whose genetic or laboratory test results are not yet complete or are inconclusive

Who may not be able to join:

  • People for whom the necessary information needed to place them in the correct study group is missing or unavailable
  • People (or their legal guardians) who have not signed the required consent form to participate in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Joseph P Dewulf, M.D., Ph.D., Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phone: 02/7646836

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Registry
ClinicalTrials.gov
Start date
3 January 2024
Est. completion
1 January 2028

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Uncover new biomarkers in dried blood spots and urines samples able to improve the diagnosis of rare diseases

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov